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Abstract:	  31	   Genetic	  analysis	  of	  late-­‐onset	  Alzheimer’s	  disease	  risk	  has	  previously	  identified	  a	  32	   network	  of	  largely	  microglial	  genes	  that	  form	  a	  transcriptional	  network.	  	  In	  33	   transgenic	  mouse	  models	  of	  amyloid	  deposition	  we	  have	  previously	  shown	  that	  34	   the	  expression	  of	  many	  of	  the	  mouse	  orthologs	  of	  these	  genes	  are	  co-­‐ordinately	  35	   up-­‐regulated	  by	  amyloid	  deposition.	  	  Here	  we	  investigate	  whether	  systematic	  36	   analysis	  of	  other	  members	  of	  this	  mouse	  amyloid-­‐responsive	  network	  predicts	  37	   other	  Alzheimer’s	  risk	  loci.	  	  This	  statistical	  comparison	  of	  the	  mouse	  amyloid-­‐38	   response	  network	  with	  Alzheimer’s	  disease	  genome-­‐wide	  association	  studies	  39	   identifies	  5	  other	  genetic	  risk	  loci	  for	  the	  disease	  (OAS1,	  CXCL10,	  LAPTM5,	  ITGAM	  40	   and	  LILRB4).	  	  This	  work	  suggests	  that	  genetic	  variability	  in	  the	  microglial	  41	   response	  to	  amyloid	  deposition	  is	  a	  major	  determinant	  for	  Alzheimer’s	  risk.	  42	   	  43	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Main	  Text:	  58	   All	  the	  mutations	  in	  the	  genes	  causing	  early-­‐onset	  Alzheimer’s	  disease	  (AD)	  alter	  59	   APP	  processing	  such	  that	  amyloid	  deposition	  becomes	  more	  likely	  (1).	  	  In	  60	   contrast,	  with	  the	  exception	  of	  some	  rare	  variants	  in	  APP	  processing	  enzymes	  (2-­‐61	  
5),	  the	  majority	  of	  the	  risk	  in	  late-­‐onset	  disease	  has	  been	  shown	  to	  be	  due	  to	  62	   sequence	  variability	  in	  genes	  expressed	  in	  the	  innate	  immune	  system	  (largely	  63	   microglial)	  and	  lipid	  metabolism	  (6).	  	  When	  we	  identified	  the	  microglial	  gene	  64	  
TREM2	  (7)	  as	  a	  potent	  risk	  gene	  for	  late-­‐onset	  disease,	  we	  confirmed	  earlier	  65	   reports	  that	  its	  expression	  was	  strongly	  increased	  by	  amyloid	  deposition	  in	  APP	  66	   transgenic	  mice	  (7-­‐10).	  	  In	  a	  genome-­‐wide	  expression	  study	  of	  transgenic	  67	  
APP/PSEN1	  mice	  during	  pathology	  development,	  we	  noted	  that	  Trem2	  was	  one	  68	   of	  the	  genes	  whose	  expression	  was	  up-­‐regulated	  the	  most	  in	  relation	  to	  amyloid	  69	   deposition	  and	  that	  Trem2	  expression	  showed	  a	  strong	  correlation	  with	  an	  70	   entire	  network	  of	  genes	  co-­‐expressed	  in	  the	  innate	  immune	  system.	  This	  71	   immune	  module	  of	  genes	  showed	  a	  remarkable	  correlation	  to	  amyloid	  pathology	  72	   and	  contained	  orthologs	  of	  other	  established	  Alzheimer’s	  risk	  genes	  such	  as	  73	  
Abca7	  and	  Ms4a6d	  (correlation	  =	  0.87;	  p	  =	  6e-­‐32)(9,	  11).	  Notably,	  the	  two	  AD	  risk	  74	   loci	  for	  ABI3	  and	  PLCG2	  identified	  subsequent	  to	  our	  study	  were	  also	  present	  in	  75	   this	  network	  (12),	  suggesting	  that	  this	  amyloid-­‐responsive	  immune	  network	  may	  76	   predict	  future	  risk	  genes	  for	  AD.	  77	   An	  important	  outstanding	  question	  is	  whether	  late-­‐onset	  AD	  is	  mostly	  due	  to	  an	  78	   inadequate	  cellular	  response	  to	  rising	  Aβ	  and	  its	  deposition,	  particularly	  due	  to	  79	   sequence	  and	  expression	  variability	  in	  genes	  expressed	  by	  the	  innate	  immune	  80	   system	  and/or	  involved	  in	  lipid	  processing.	  This	  hypothesis	  is	  difficult	  to	  study	  81	   in	  human	  post-­‐mortem	  tissue	  because	  after	  an	  extended	  period	  of	  disease	  the	  82	   proportion	  of	  cell	  types	  in	  the	  brain	  have	  changed	  and	  the	  remaining	  cells	  show	  83	   extensive	  compensatory	  changes	  in	  gene	  expression.	  With	  these	  questions	  in	  84	   mind,	  we	  determined	  whether	  surveying	  the	  gene	  expression	  network	  that	  85	   responds	  robustly	  to	  amyloid	  pathology	  could	  be	  used	  to	  identify	  further	  AD	  risk	  86	   loci.	  	  Although	  amyloid	  mouse	  models	  have	  clear	  limitations	  in	  that	  they	  do	  not	  87	   show	  tau	  tangles	  or	  neuronal	  loss,	  they	  allow	  us	  to	  study	  the	  time-­‐course	  88	   response	  of	  a	  healthy	  innate	  immune	  system	  reacting	  to	  Aβ,	  in	  which	  the	  innate	  89	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immune	  cells	  have	  the	  ability	  to	  ultimately	  prevent	  Aβ	  killing	  neurons.	  Our	  90	   previous	  expression	  network	  was	  constructed	  using	  expression	  arrays	  (9).	  	  91	   Because	  these	  microarrays	  are	  limited	  by	  their	  probe	  content	  and	  have	  a	  limited	  92	   dynamic	  range,	  we	  have	  now	  sequenced	  the	  transcriptome	  using	  RNA-­‐seq	  and	  93	   reconstructed	  a	  higher	  resolution	  expression	  network.	  	  The	  new	  full	  microglial	  94	   module	  of	  genes	  shows	  a	  dramatic	  correlation	  with	  Aβ	  pathology	  (correlation	  =	  95	   0.94;	  p	  <	  3e-­‐41),	  and	  contains	  the	  mouse	  orthologs	  of	  existing	  GWAS	  loci	  TREM2,	  96	  
ABI3,	  CD33,	  INPP5D,	  MS4A6D,	  SPI1,	  PLCG2,	  RIN3,	  HLA	  and	  APOE	  (Table	  S1).	  The	  97	   genes	  showing	  the	  tightest	  expression	  correlation/Aβ-­‐response	  within	  the	  98	   module	  form	  the	  network	  shown	  in	  Fig.	  1	  and	  Table	  S2	  (top	  147	  genes	  from	  a	  99	   total	  of	  1,584	  genes	  with	  up-­‐regulated	  expression	  as	  part	  of	  the	  immune	  module	  100	   based	  on	  the	  topological	  overlap	  measure,	  TOM,	  see	  Methods).	  This	  network	  is	  101	   broadly	  similar	  to	  the	  network	  derived	  from	  the	  analysis	  of	  the	  same	  RNA	  by	  102	   microarray	  methods	  (9),	  and	  importantly	  closely	  resembles	  microglial	  networks	  103	   published	  by	  other	  groups	  using	  different	  amyloid	  mouse	  models	  (13-­‐17),	  104	   suggesting	  this	  is	  a	  conserved	  network	  of	  genes	  that	  can	  be	  reliably	  identified	  105	   using	  different	  methodologies.	  Trem2	  forms	  a	  hub	  gene	  in	  our	  network	  106	   indicating	  that	  Trem2	  expression	  is	  highly	  correlated	  to	  many	  other	  genes	  in	  the	  107	   network,	  and	  may	  drive	  the	  expression	  response	  of	  this	  network.	  In	  line	  with	  this	  108	   idea,	  Trem2	  has	  been	  shown	  to	  regulate	  at	  least	  part	  of	  this	  immune	  module	  (13,	  109	  
14,	  16).	  The	  network	  we	  identified	  also	  is	  broadly	  similar	  to	  a	  human	  network	  of	  110	   immune	  genes	  containing	  TYROBP,	  TREM2,	  MS4A	  family	  genes,	  C1Q	  members	  111	   and	  CD33,	  identified	  from	  human	  pathology	  tissue	  bearing	  in	  mind	  the	  caveats	  112	   discussed	  above	  (18,	  19),	  suggesting	  this	  mouse	  Aβ-­‐response	  gene	  network	  113	   behaves	  similarly	  in	  humans.	  114	   Within	  our	  mouse	  immune	  network,	  we	  first	  confirmed	  that	  several	  members	  115	   were	  orthologs	  of	  AD	  loci	  variants	  using	  the	  data	  from	  the	  Alzheimer’s	  disease	  116	   genetic	  consortium	  (11,	  20)(Table	  1).	  We	  then	  asked	  whether	  the	  other	  members	  117	   of	  the	  mouse	  microglial	  amyloid-­‐response	  network	  overlapped	  with	  individual	  118	   human	  genes	  containing	  multiple	  SNPs	  associated	  with	  AD	  by	  cross-­‐referencing	  119	   gene-­‐based	  statistical	  approaches	  (20).	  Overall,	  we	  found	  there	  was	  an	  120	   enrichment	  of	  human	  genes	  with	  significant	  AD-­‐associated	  SNPs	  within	  this	  121	   amyloid-­‐responsive	  network.	  	  This	  enrichment	  was	  more	  than	  would	  be	  122	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expected	  by	  chance	  alone,	  even	  after	  the	  established	  GWAS	  loci	  were	  excluded	  (p	  123	   =	  1.91x10-­‐5	  for	  highly	  connected	  network	  genes,	  Fig.	  1,	  top	  147	  genes,	  versus	  p	  =	  124	   7.32x10-­‐4	  for	  the	  entire	  module	  of	  1,584	  genes,	  Table	  S1).	  	  As	  a	  comparison	  to	  the	  125	   mouse	  amyloid-­‐responsive	  network,	  the	  mouse	  tau-­‐responsive	  immune	  network	  126	   was	  not	  significantly	  enriched	  for	  human	  genes	  with	  AD-­‐associated	  SNPs	  when	  127	   the	  central	  portion	  of	  the	  tau	  network	  containing	  the	  highly	  connected	  genes	  128	   were	  considered,	  after	  the	  established	  GWAS	  loci	  were	  excluded	  as	  before	  (p	  =	  129	   0.92),	  although	  Apoe	  is	  part	  of	  this	  module	  (Fig.	  S1,	  top	  137	  genes	  from	  a	  total	  of	  130	   2,299	  genes	  in	  the	  immune	  module	  based	  on	  the	  TOM).	  	  When	  the	  entire	  module	  131	   of	  tau-­‐responsive	  immune	  genes	  (2,299	  genes)	  was	  considered	  there	  was	  a	  132	   significant	  enrichment,	  p	  =	  4.63x10-­‐6,	  suggesting	  that	  a	  proportion	  of	  AD-­‐133	   associated	  SNPs	  appear	  in	  microglial	  genes	  that	  have	  mouse	  orthologs,	  but	  are	  134	   less	  responsive	  to	  tau	  pathology	  compared	  to	  amyloid	  pathology.	  	  The	  amyloid	  135	   network	  analyses	  identified	  5	  genes	  within	  the	  mouse	  microglial	  network	  whose	  136	   human	  orthologes	  contained	  SNPs	  significantly	  associated	  with	  AD,	  counting	  the	  137	   genes	  within	  0.5	  Mb	  as	  one	  locus	  (see	  Methods,	  20).	  These	  5	  genes,	  OAS1,	  138	  
CXCL10,	  LAPTM5,	  ITGAM	  and	  LILRB4,	  have	  not	  been	  previously	  reported	  as	  139	   having	  variants	  significantly	  associated	  with	  AD	  using	  traditional	  GWAS	  140	   approaches	  (Table	  1,	  Fig.	  S2-­‐4).	  	  Indeed	  the	  amyloid-­‐responsive	  sub-­‐network	  of	  141	   these	  5	  novel	  genes	  with	  the	  established	  GWAS	  loci	  TREM2,	  ABI3,	  CD33,	  INPP5D,	  142	  
SPI1	  and	  MS4A6D	  (Fig.	  1)	  is	  not	  highly	  connected	  in	  an	  innate	  immune	  gene	  143	   network	  associated	  with	  tau	  pathology	  (Fig.	  S1),	  suggesting	  this	  sub-­‐network	  is	  144	   more	  responsive	  to	  amyloid	  pathology	  than	  other	  pathologies.	  Furthermore,	  in	  145	   common	  with	  the	  existing	  6	  known	  GWAS-­‐associated	  genes,	  the	  5	  novel	  genes	  146	   we	  identify	  respond	  very	  early	  to	  Aβ	  deposition,	  with	  gene	  expression	  increasing	  147	   from	  4	  months	  of	  age	  in	  the	  homozygous	  APP/PSEN1	  mice	  (Fig.	  S5).	  	  148	   Aspects	  of	  the	  amyloid-­‐responsive	  network	  we	  identify	  in	  our	  analysis	  149	   containing	  the	  5	  new	  genes	  with	  the	  existing	  6	  GWAS	  loci	  are	  broadly	  similar	  to	  150	   microglial	  networks	  we	  and	  others	  have	  previously	  identified	  in	  human	  brain	  151	   analyses.	  	  Zhang	  and	  colleagues	  identified	  an	  AD-­‐relevant	  network	  centered	  on	  152	  
TYROBP	  and	  TREM2	  which	  contained	  ITGAM	  and	  LAPTM5	  (18)	  and	  we	  described	  153	   a	  human	  microglial	  network	  containing	  LAPTM5,	  ITGAM	  and	  LILRB4	  (19).	  We	  154	   then	  determined	  whether	  these	  novel	  Alzheimer’s	  risk	  loci,	  derived	  from	  a	  155	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mouse	  Aβ-­‐response	  network	  were	  present	  in	  independent	  datasets	  of	  human	  156	   brain	  co-­‐expression	  networks.	  	  Cross	  referencing	  the	  network	  (see	  Methods)	  157	   with	  the	  data	  from	  the	  ROS/MAP	  project	  (21,	  22),	  and	  BRAINEAC	  (23)	  datasets	  158	   revealed	  that	  LAPTM5,	  ITGAM	  and	  LILRB4	  clustered	  together	  in	  the	  same	  159	   network	  in	  the	  ROSMAP	  based	  co-­‐expression	  networks,	  together	  with	  many	  of	  160	   the	  GWAS	  risk	  genes	  for	  AD,	  and	  with	  SPI1,	  the	  myeloid	  cell	  transcription	  factor	  161	   (24)(Fig.	  S6;	  Fisher’s	  Exact	  test	  Bonferroni	  corrected	  p	  =	  1.34x10-­‐13	  for	  AD).	  We	  162	   confirmed	  these	  module	  memberships	  in	  the	  BRAINEAC	  data	  for	  control	  brains	  163	   generated	  in	  our	  own	  lab	  and	  found	  essentially	  the	  same	  results	  (data	  not	  164	   shown).	  Interestingly,	  we	  found	  that	  SPI1	  was	  bound	  to	  the	  regulatory	  regions	  of	  165	  
Laptm5	  and	  Itgam,	  along	  with	  binding	  to	  established	  AD	  risk	  gene	  orthologs	  166	  
Trem2,	  Abi3,	  Inpp5d,	  Ms4a6d	  and	  Spi1	  itself,	  by	  searching	  data	  from	  a	  chromatin	  167	   immunoprecipitation	  experiment	  against	  SPI1	  in	  mouse	  microglial-­‐like	  BV-­‐2	  168	   cells	  (25).	  This	  finding	  was	  supported	  by	  mining	  for	  regulatory	  features	  and	  cis-­‐169	   regulatory	  modules	  in	  the	  amyloid-­‐response	  network	  genes	  using	  i-­‐cisTarget	  170	   that	  uses	  a	  vast	  library	  of	  regulatory	  data	  (26).	  Together,	  these	  findings	  suggest	  171	   that	  a	  number	  of	  the	  predicted	  and	  established	  AD	  risk	  genes	  may	  be	  regulated	  172	   by	  SPI1,	  which	  itself	  alters	  AD	  risk	  by	  coordinating	  a	  program	  of	  microglial-­‐173	   expressed	  genes	  (24).	  174	   Since	  most	  GWAS	  loci	  are	  thought	  to	  operate	  by	  regulating	  the	  expression	  of	  175	   neighboring	  genes	  (24,	  27,	  28),	  for	  each	  of	  the	  5	  potential	  AD-­‐associated	  genes	  176	   we	  performed	  a	  colocalisation	  analysis	  to	  test	  the	  association	  between	  AD	  loci	  177	   located	  within	  these	  genes	  and	  loci	  regulating	  these	  genes’	  expression	  (eQTLs;	  178	   (29).	  eQTLs	  were	  obtained	  from	  two	  previously	  published	  datasets	  using	  179	   baseline	  and	  stimulated	  human-­‐derived	  monocytes	  and	  iPSC-­‐derived	  180	   macrophages	  (30,	  31).	  In	  these	  studies,	  macrophages	  and	  monocytes	  were	  181	   stimulated	  with	  various	  immunostimulants	  to	  activate	  distinct,	  well-­‐182	   characterised	  immune	  signaling	  pathways,	  including	  those	  broadly	  associated	  183	   with	  bacterial	  and	  viral	  responses.	  Interestingly,	  we	  identified	  3	  colocalisations	  184	   between	  AD	  loci	  and	  eQTLs	  regulating	  OAS1	  gene	  expression,	  all	  of	  which	  were	  185	   identified	  in	  stimulated	  states,	  suggesting	  that	  this	  association	  is	  only	  active	  in	  186	   certain	  environmental	  conditions	  (Fig.	  2	  and	  Fig.	  S7-­‐8),	  in	  particular	  those	  187	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designed	  to	  model	  monocyte/macrophage	  priming	  or	  more	  chronic	  188	   inflammation.	  	  	  189	   Surveying	  the	  literature	  on	  our	  genes	  of	  interest	  revealed	  that	  OAS1	  (2-­‐prime,5-­‐190	   prime	  oligoadenylate	  synthetase	  1)	  is	  involved	  in	  the	  regulation	  of	  cytokine	  191	   expression	  (32).	  	  OAS1	  is	  induced	  by	  interferons	  (33),	  which	  supports	  our	  eQTL	  192	   analysis	  showing	  that	  the	  best	  SNP	  we	  identified	  for	  OAS1	  appears	  in	  a	  locus	  193	   which	  acts	  as	  an	  eQTL	  in	  response	  to	  interferon-­‐γ	  (IFNγ;	  Fig.	  2	  and	  Fig.	  S7-­‐8).	  194	  
OAS1	  can	  additionally	  activate	  Ribonuclease	  L	  which	  degrades	  viral	  RNA	  and	  195	   inhibits	  viral	  replication	  (33).	  CXCL10	  (IP-­‐10;	  chemokine,	  CXC	  motif,	  ligand	  10)	  is	  196	   a	  proinflammatory	  cytokine	  that	  has	  been	  reported	  to	  have	  increased	  197	   concentrations	  in	  the	  AD-­‐brain,	  particularly	  associated	  with	  amyloid	  plaques	  198	   (34),	  and	  CXCL10	  increases	  plaque	  pathology	  in	  APP/PSEN1	  transgenic	  mice	  (35).	  199	  
CXCL10	  was	  found	  to	  increase	  in	  older	  people	  and	  in	  AD,	  and	  correlated	  with	  200	   cognitive	  decline	  (36).	  LAPTM5	  (lysosome-­‐associated	  protein,	  transmembrane	  5)	  201	   is	  associated	  with	  amyloid	  pathology	  in	  transgenic	  mice	  (17),	  and	  LILRB4	  202	   (leukocyte	  immunoglobulin-­‐like	  receptor,	  subfamily	  B,	  member	  4),	  has	  also	  been	  203	   shown	  to	  be	  increased	  with	  amyloid	  pathology	  and	  specifically	  associated	  with	  204	   amyloid	  plaques	  (15,	  37,	  38).	  The	  functions	  of	  LAPTM5	  and	  LILRB4	  have	  not	  been	  205	   well	  characterized,	  but	  are	  thought	  to	  suppress	  the	  activation	  of	  a	  variety	  of	  206	   immune	  cells.	  	  ITGAM	  (alpha-­‐chain	  subunit	  of	  the	  heterodimeric	  integrin	  207	   complement	  receptor	  alpha-­‐M-­‐beta-­‐2,	  also	  known	  as	  CD11b	  or	  CR3A),	  is	  a	  cell	  208	   surface	  receptor	  involved	  in	  activation,	  migration	  and	  phagocytosis	  of	  immune	  209	   cells,	  so	  much	  so	  that	  ITGAM	  is	  used	  as	  a	  marker	  of	  activated	  microglia	  (37,	  39,	  210	  
40),	  and	  is	  involved	  in	  systemic	  lupus	  (41).	  ITGAM	  was	  highlighted	  in	  recent	  211	   genetic	  and	  functional	  analyses	  as	  being	  a	  likely	  AD	  risk	  gene,	  whose	  expression	  212	   was	  driven	  by	  SPI1,	  and	  related	  to	  amyloid	  pathology	  in	  mice	  and	  humans	  (17,	  213	  
18,	  24,	  37,	  42,	  43).	  214	   The	  importance	  of	  this	  work	  is	  two	  fold.	  	  First,	  by	  identifying	  more	  genetic	  loci	  215	   involved	  in	  pathogenesis,	  we	  derive	  a	  more	  complete	  insight	  into	  the	  cellular	  216	   processes	  and	  molecular	  mechanisms	  underlying	  the	  disease.	  	  In	  this	  regard	  this	  217	   work	  is	  complementary	  to	  that	  of	  Huang	  and	  colleagues	  (24),	  showing	  that	  218	   microglial	  SPI1-­‐driven	  transcription	  is	  a	  common	  feature	  of	  many	  Alzheimer’s	  219	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loci.	  	  These	  findings	  are	  also	  consistent	  with	  previous	  work	  on	  Trem2	  (8,	  13,	  14,	  220	  
16,	  44)	  and	  CD33	  (27,	  28)	  suggesting	  these	  risk	  genes	  are	  crucial	  in	  controlling	  221	   the	  microglial	  response	  to	  amyloid-­‐induced	  damage.	  Understanding	  the	  222	   mechanisms	  of	  function	  of	  TREM2	  and	  the	  amyloid-­‐responsive	  sub-­‐network	  223	   identified	  here	  may	  be	  useful	  for	  leveraging	  therapeutic	  opportunities.	  Second,	  224	   and	  perhaps	  of	  greater	  importance,	  this	  work	  implies	  that,	  overall,	  how	  well	  an	  225	   individual	  responds	  to	  amyloid	  deposition	  at	  the	  cellular	  and	  gene	  expression	  226	   level	  plays	  a	  large	  part	  in	  determining	  ones	  risk	  of	  disease,	  and	  this	  may	  be	  used	  227	   to	  predict	  the	  chances	  of	  developing	  AD	  before	  irreversible	  neurodegeneration	  228	   sets	  in.	  229	  
URLs	  of	  databases	  used:	  230	   Mouseac:	  www.mouseac.org	  231	   Braineac:	  www.braineac.org	  232	   1,000	  genomes:	  http://www.1000genomes.org/	  and	  233	   http://www.internationalgenome.org/	  234	   Coloc:	  https://github.com/chr1swallace/coloc	  235	   Bioconductor:	  https://bioconductor.org/biocLite.R	  236	   ROS/MAP:	  https://www.synapse.org/#!Synapse:syn3219045	  237	   i-­‐CisTarget:	  https://gbiomed.kuleuven.be/apps/lcb/i-­‐cisTarget/	  238	   GTEx	  V6	  gene	  expression:	  https://gtexportal.org/home/	  239	   Coexp:	  https://github.com/juanbot/coexp	  240	   	  241	  
Methods:	  242	  
Mouse	  and	  transcriptome	  work	  243	   Total	  RNA	  was	  used	  from	  the	  same	  mice	  as	  described	  in	  Matarin	  et	  al.	  (9).	  The	  244	   quality	  and	  concentration	  of	  the	  total	  RNA	  was	  assessed	  using	  capillary	  245	   electrophoresis	  of	  each	  sample.	  RNA-­‐seq	  library	  preparation	  and	  sequencing	  was	  246	   performed	  by	  Eurofins	  Genomics	  (strand-­‐specific	  cDNA	  libraries	  with	  polyA	  247	   selection),	  by	  Illumina	  (HiSeq	  2500)	  sequencing	  (2x	  100	  bp	  paired-­‐end;	  248	   multiplex	  12	  samples	  per	  lane	  -­‐	  28M	  reads).	  Adaptors	  and	  low	  quality	  base	  pairs	  249	   were	  removed	  from	  FASTQ	  files	  using	  Trim	  Galore	  (Babraham	  Bioinformatics).	  250	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Transcripts	  were	  quantified	  with	  Salmon	  (45),	  using	  gene	  annotation	  from	  251	   ENSEMBL	  GRCm38.	  Salmon	  was	  used	  because	  it	  incorporates	  GC	  correction	  and	  252	   accounts	  for	  fragment	  positional	  bias.	  To	  get	  gene	  level	  quantification	  from	  the	  253	   transcripts,	  and	  correct	  for	  average	  transcript	  length	  and	  library	  size,	  expressed	  254	   as	  transcripts	  per	  million	  (TPM),	  the	  tximport	  R	  package	  was	  used	  (46).	  TPM	  255	   values	  were	  log2	  transformed,	  and	  genes	  were	  considered	  expressed	  when	  log2	  256	   TPM	  values	  displayed	  a	  mean	  >1.5	  for	  a	  given	  gene	  for	  at	  least	  one	  group	  of	  mice,	  257	   when	  gene	  TPM	  values	  were	  averaged	  for	  each	  genotype	  at	  each	  age	  (resulting	  in	  258	   a	  total	  of	  18,562	  genes	  expressed).	  259	   Weighted	  	  co-­‐expression	  network	  analyses	  (WGCNAs)	  was	  performed	  as	  260	   described	  in	  Matarin	  et	  al.	  (9).	  Coexpression	  networks	  were	  built	  using	  the	  261	   WGCNA	  package	  in	  R.	  Genes	  with	  variable	  expression	  patterns	  (coefficient	  of	  262	   variation	  >5%	  for	  wild-­‐type	  and	  amyloid	  mice,	  or	  wild-­‐type	  and	  tau	  mice)	  from	  263	   normalized	  log2	  TPM	  values	  were	  selected	  for	  network	  analyses	  resulting	  in	  264	   13,536	  genes	  for	  network	  analyses	  (47-­‐50).	  The	  module	  of	  genes	  with	  the	  265	   highest	  significant	  correlation	  with	  amyloid	  or	  tau	  pathology	  was	  selected	  for	  266	   analysis	  (amyloid,	  correlation	  0.94,	  p	  =	  3e-­‐41;	  tau,	  correlation	  0.82,	  p	  =4e-­‐12).	  267	   TOM	  connectivity	  values	  were	  used	  to	  plot	  the	  network	  diagrams	  (TOM	  >	  0.39	  268	   for	  amyloid-­‐responsive	  module,	  and	  TOM	  >	  0.36	  for	  tau-­‐responsive	  module).	  269	   Hub	  genes	  were	  considered	  to	  be	  those	  with	  at	  least	  15	  connections	  to	  other	  270	   genes.	  271	  
Genetic	  Analysis	  272	   The	  lists	  of	  mouse	  genes	  were	  converted	  to	  the	  lists	  of	  human	  genes	  using	  273	   convertMouseGeneList()	  function,	  library	  	  biomaRt	  in	  R	  downloaded	  from	  	  274	   https://bioconductor.org/biocLite.R.	  	  275	   The	  significance	  of	  the	  association	  of	  human	  genes	  to	  AD	  was	  assessed	  as	  276	   described	  in	  (20).	  Briefly,	  the	  IGAP	  (11)	  summary	  statistics	  calculated	  for	  each	  277	   SNP	  in	  a	  sample	  of	  17,008	  AD	  cases	  and	  37,154	  controls	  were	  used	  to	  derive	  the	  278	   gene-­‐based	  p-­‐values.	  SNPs	  were	  assigned	  to	  genes	  if	  they	  were	  located	  within	  279	   the	  genomic	  sequence	  lying	  between	  the	  start	  of	  the	  first	  and	  the	  end	  of	  the	  last	  280	   exon	  of	  any	  transcript	  corresponding	  to	  that	  gene.	  The	  chromosome	  and	  location	  281	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for	  all	  currently	  known	  human	  SNPs	  along	  with	  their	  assignment	  to	  genes	  were	  282	   taken	  from	  the	  dbSNP132	  database	  (build	  37.1).	  If	  a	  SNP	  belongs	  to	  more	  than	  283	   one	  gene,	  it	  was	  assigned	  to	  each	  of	  these	  genes.	  Data	  from	  the	  1,000	  genomes	  284	   project	  (release	  Dec2010)	  were	  used	  as	  a	  reference	  panel	  for	  both	  (a)	  SNP	  285	   imputation,	  and	  	  (b)	  calculation	  of	  LD	  between	  markers	  (51).	  An	  approximate	  286	   statistical	  approach	  (52)	  which	  controls	  for	  LD	  and	  different	  number	  of	  markers	  287	   per	  gene,	  was	  used	  to	  derive	  the	  gene-­‐based	  p-­‐values.	  Prior	  to	  the	  gene-­‐based	  288	   analyses	  all	  individual	  SNP	  p-­‐values	  were	  corrected	  for	  genomic	  control.	  	  289	   We	  calculated	  the	  significance	  of	  the	  excess	  number	  of	  genes	  attaining	  the	  290	   specified	  thresholds	  (0.05,	  0.01	  and	  0.001)	  based	  upon	  the	  assumption	  that,	  291	   under	  the	  null	  hypothesis	  of	  no	  association,	  the	  number	  of	  significant	  genes	  at	  a	  292	   significance	  level	  of	  α	  in	  a	  scan	  is	  distributed	  as	  a	  binomial	  (N,	  α),	  where	  N	  is	  the	  293	   total	  number	  of	  genes,	  assuming	  that	  genes	  are	  independent.	  Genes	  within	  0.5Mb	  294	   of	  each	  other	  are	  counted	  as	  one	  signal	  when	  calculating	  the	  observed	  number	  of	  295	  
significant	  genes.	  This	  prevents	  significance	  being	  inflated	  by	  LD	  between	  genes,	  296	   where	  a	  single	  association	  signal	  gives	  rise	  to	  several	  significantly-­‐associated	  297	   genes.	  The	  over-­‐representation	  p-­‐value	  was	  calculated	  using	  a	  Z-­‐test	  comparing	  298	   the	  number	  of	  observed	  independent	  significant	  genes	  with	  the	  expected	  299	   number	  of	  significant	  genes	  with	  corresponding	  variance	  (=N*a	  *(1-­‐	  a	  ),	  where	  N	  300	   is	  the	  total	  number	  of	  independent	  genes	  in	  the	  network,	  and	  a	  is	  the	  significance	  301	   threshold).	  We	  report	  the	  genes	  at	  the	  gene-­‐based	  p-­‐value	  threshold	  0.01,	  where	  302	   the	  excess	  of	  observed	  significant	  genes	  was	  the	  highest.	  303	  
Human	  sample	  co-­‐expression	  network	  construction	  and	  annotation	  304	   We	  generated	  co-­‐expression	  networks	  from	  RNA-­‐seq	  based	  gene	  expression	  305	   profiling	  of	  635	  pre-­‐frontal	  cortex	  samples	  from	  the	  ROS/MAP	  project	  (21,	  22,	  306	  
53).	  We	  used	  cognitive	  decline	  as	  a	  covariate	  to	  construct	  four	  networks:	  all	  307	   samples	  network,	  not	  AD,	  probable	  AD	  and	  AD.	  We	  used	  WGCNA	  (50)	  with	  an	  308	   optimization	  for	  constructing	  more	  biologically	  meaningful	  co-­‐expression	  309	   networks	  (54).	  We	  corrected	  for	  batch	  effects	  using	  ComBAT	  (55),	  obtained	  310	   unknown	  hidden	  effect	  covariates	  with	  SVA	  (56),	  and	  used	  the	  residuals	  311	   obtained	  by	  regressing	  the	  gene	  expression	  with	  SVA	  covariates,	  age	  and	  gender.	  312	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Then	  we	  annotated	  the	  network	  modules	  for	  enrichment	  of	  Gene	  Ontology,	  313	   REACTOME	  (57),	  and	  KEGG	  (58)	  pathways	  using	  gProfileR	  (59).	  314	  
	  315	  
Colocalisation	  with	  monocyte	  eQTL	  data	  sets	  316	   We	  applied	   coloc	   (version	  3.1,	   see	  URLs)	   to	   test	   for	   colocalisation	  between	  AD	  317	   loci	  surrounding	  the	  five	  novel	  identified	  genes	  (OAS1,	  CXCL10,	  LAPTM5,	  ITGAM,	  318	   and	  LILRB4)	   and	   eQTLs	   (29).	  While	   no	  microglial	   eQTL	   datasets	   exist	   to	   date,	  319	   eQTL	   analyses	   have	   been	   performed	   using	   monocytes	   and	   iPSC-­‐derived	  320	   macrophages	   (at	   rest	   and	   stimulated	  with	   various	   immunostimulants,	   such	   as	  321	   IFN-­‐γ)(30,	   31).	  We	   ran	   coloc	   using	   default	   parameters	   and	   priors	   on	   all	   SNPs	  322	   that:	  1)	  had	  eQTLs	  tagging	  one	  of	  the	  5	  novel	  genes	  (this	  included	  all	  tested	  SNP-­‐323	   gene	   associations,	   including	   non-­‐significant	   eQTLs);	   and	   2)	   had	   overlapping	  324	   SNPs	  in	  the	  AD	  GWAS.	  We	  excluded	  all	  loci	  in	  which	  PP3	  +	  PP4	  <	  0.8,	  to	  exclude	  325	   loci	  where	  we	  were	  underpowered	  to	  detect	  colocalisation.	  Loci	  with	  PP4/PP3	  ≥	  326	   2	   were	   considered	   colocalised	   due	   to	   a	   single	   shared	   causal	   variant	   (PP4),	   as	  327	   opposed	  to	  two	  distinct	  causal	  variants	  (PP3).	  328	   	  329	   	  330	   	  331	   	  332	   	  333	   	  334	   	  335	   	  336	   	  337	   	  338	   	  339	   	  340	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Fig.	  1.	  Amyloid-­‐responsive	  immune	  network	  of	  genes	  featuring	  several	  341	  
orthologs	  of	  established	  GWAS	  variants	  associated	  with	  AD,	  predicts	  the	  342	  
importance	  of	  five	  new	  genes	  that	  may	  influence	  the	  risk	  of	  developing	  AD.	  343	   Network	  plot	  using	  VisANT	  reveals	  key	  drivers	  of	  an	  immune	  module	  from	  RNA-­‐344	   seq	  derived	  gene	  expression	  from	  the	  hippocampus	  of	  wild-­‐type	  and	  amyloid	  345	   mice.	  Red	  circles	  show	  established	  GWAS	  genes	  associated	  with	  AD	  including	  346	  
Trem2,	  Cd33,	  Abi3	  and	  Spi1.	  Blue	  underline	  shows	  genes	  predicted	  to	  confer	  347	   increased	  risk	  of	  AD	  by	  overlapping	  strongly	  amyloid-­‐responsive	  gene	  348	   expression	  data	  in	  amyloid	  mice	  with	  analyses	  identifying	  combinations	  of	  349	   adjacent	  human	  SNPs	  within	  individual	  genes	  showing	  significant	  associations	  350	   with	  AD	  (see	  Methods,	  20).	  Genes	  shown	  in	  this	  network	  display	  up-­‐regulated	  351	   expression	  in	  response	  to	  amyloid	  deposition.	  Larger	  red	  spheres	  represent	  ‘‘hub	  352	   genes,’’	  those	  showing	  the	  greatest	  number	  of	  connections	  to	  other	  genes	  in	  the	  353	   network,	  and	  include	  Trem2,	  Tryobp,	  Lilrb4a,	  P2ry13,	  Ctss,	  Ctsz,	  Mpeg1	  and	  Plek,	  354	   which	  are	  likely	  to	  play	  important	  roles	  in	  driving	  microglial	  function.	  	  355	   	  356	  
Fig.	  2.	  Colocalisation	  of	  AD	  GWAS	  loci	  with	  eQTLs	  derived	  from	  baseline	  357	  
and	  stimulated	  iPSC-­‐derived	  macrophages.	  Colocalisation	  of	  AD	  loci	  and	  358	   eQTLs	  targeting	  OAS1	  in	  baseline	  and	  stimulated	  states	  (IFNγ	  and	  Salmonella,	  18	  359	   and	  5	  hours	  respectively).	  In	  the	  eQTL	  panels,	  grey	  and	  red	  data	  points	  represent	  360	   macrophages	  at	  baseline	  or	  stimulated	  with	  both	  IFNγ	  and	  Salmonella,	  361	   respectively.	  The	  best	  AD	  locus	  in	  OAS1,	  rs1131454	  (p-­‐value	  =	  3.92	  x	  10-­‐5),	  is	  362	   highlighted	  with	  the	  black	  line.	  IFNγ,	  interferon-­‐γ.	  Numerical	  results	  are	  363	   reported	  in	  Table	  S3.	  364	   	  365	  
Table	  1.	  The	  genes	  predicted	  to	  contain	  SNP	  variants	  associated	  with	  AD	  366	  
together	  with	  established	  loci	  associated	  with	  AD	  from	  GWAS.	  Genes	  367	   predicted	  to	  confer	  increased	  risk	  of	  AD	  by	  overlapping	  strongly	  amyloid-­‐368	   responsive	  gene	  expression	  data	  in	  amyloid	  mice	  (Fig.	  1)	  with	  analyses	  369	   identifying	  combinations	  of	  adjacent	  human	  SNPs	  within	  individual	  genes	  370	   showing	  significant	  associations	  with	  AD	  (see	  Methods;	  20).	  The	  SNP	  positions	  371	   are	  provided	  for	  build	  37,	  assembly	  Hg19,	  as	  in	  IGAP	  study	  (11).	  The	  SNP	  with	  372	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the	  most	  significant	  p-­‐value	  within	  each	  gene	  is	  denoted	  as	  ‘Best	  SNP,’	  from	  the	  373	   IGAP	  stage	  1	  dataset.	  The	  effect	  size	  (coefficient	  of	  the	  logistic	  regression)	  is	  374	   provided	  for	  the	  best	  reported	  SNP	  from	  IGAP	  data;	  a	  positive	  number	  indicates	  375	   that	  the	  allele	  increases	  risk	  of	  AD,	  and	  so	  a	  negative	  number	  indicates	  the	  allele	  376	   is	  protective.	  The	  allele	  frequency	  from	  the	  IGAP	  study	  is	  also	  provided.	  The	  377	   established	  genes	  altering	  risk	  for	  AD	  from	  GWAS	  are	  given	  for	  comparison.	  378	   	  379	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Laptm5 LAPTM5 7805 1 31205315 31230683 45 0.00285 rs1623695 31210852 0.000764 -0.0817 T 0.2065 
Cxcl10 CXCL10 3627 4 76942271 76944650 6 0.00227 rs8878 76942300 0.00144 0.0508 A 0.4657 
Oas1a OAS1 4938 12 113344739 113357712 17 0.000388 rs1131454 113348870 3.92E-05 0.1004 A 0.5655 
Itgam ITGAM 3684 16 31271288 31344213 151 0.00571 rs9928397 31320901 0.000671 0.1079 T 0.0894 
Lilrb4a LILRB4 11006 19 55174124 55179848 22 0.00666 rs731170 55176262 0.000272 0.0683 A 0.3054 
Established GWAS genes 
H2-Ob HLA-DOB 3112 6 32780540 32784825 35 0.00354 rs2070121 32781554 0.00138 0.0931 A 0.0796 
Trem2 TREM2 54209 6 41126246 41130922 1 0.00258 rs7748513 41127972 0.00182 -0.1293 A 0.9633 
Spi1 SPI1 6688 11 47376409 47400127 47 1.34E-06 rs10437655 47391948 1.99E-06 0.0759 A 0.4037 
Ms4a6d MS4A6A 64231 11 59939080 59950674 22 3.07E-10 rs7935829 59942815 1.64E-10 0.1011 A 0.5989 
Abi3 ABI3 51225 17 47287589 47300587 37 0.00228 rs2158512 47290253 9.22E-07 0.154 T 0.726 
Cd33 CD33 945 19 51728335 51743274 23 1.95E-06 rs12459419 51728477 6.49E-08 -0.0945 T 0.3102 	  
Table 1. The genes predicted to contain SNP variants associated with AD together with established loci associated with AD from GWAS. 
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